Replies to post #19746 on Mymetics Corp (MYMX)

[bow-tie]

Baylor College of Medicine
Yeast and Dictyostelium

https://www.bcm.edu/departments/biochemistry-and-molecular-biology/meet-our-team/researchers/yeast-and-dictyostelium

[Work Harder]

proven yeast-based expression technology

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157292240

Thanks to the poster

One vaccine is based on a yeast-derived (Pichia pastoris) recombinant protein comprised of the receptor-binding domain (RBD) of the SARS-CoV formulated on alum and referred to as the CoV RBD219-N1 Vaccine.

Our preliminary studies now show that the SARS-CoV-2 RBD candidate, which is specific for the sequence of the SARS-CoV-2, can also be highly produced in the yeast P. pastoris. Both approaches reinforce each other, as the processes developed for the CoV RBD219-N1 candidate also apply to the SARS-CoV-2 candidate, and both antigens downstream could be further developed as potentially a bivalent or a universal coronavirus vaccine.

[Work Harder]

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and
production systems and advances in clinical development

http://media.journals.elsevier.com/content/files/s0264410x12015563-25140527.pdf